Filing Flows › Krystal Biotech (KRYS) › Q4 2025
Krystal Biotech (KRYS) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 17, 2026
Krystal Biotech (KRYS) reported revenue of $107M for the fourth quarter 2025 (Q4 2025), +18% from a year earlier and +10% from the quarter before. Operating margin was 41.3%, net earnings $51.4M (48.0% of revenue).
Krystal Biotech, Q4 2025: revenue $107M (+18% year over year), operating margin 41.3%, net earnings $51.4M, operating cash flow $77.5M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $107M | +10% | +18% |
| Operating profit | $44.3M | +7% | +7% |
| Net earnings | $51.4M | -35% | +13% |
| Operating cash flow | $77.5M | +95% | +47% |
| Free cash flow | $75.4M | +99% | +45% |
What changed
Revenue was $107.1M in Q4 2025, up 18% year over year and up 10% from the previous quarter.
Operating profit was $44.3M, a 41.3% margin (down 4.1 points year over year). Of the extra revenue versus a year earlier, 18% reached operating profit, below the 45% margin then. Total costs grew 26% against revenue growth of 18%. The fastest-growing cost line was Other operating costs (+33%). Net earnings were $51.4M, up 13% year over year. The effective tax rate was -0.5%.
Operating cash flow was $77.5M (up 47% year over year), 151% of net earnings. Non-cash charges added back $1.6M of depreciation and $13.8M of share-based compensation. Working capital and other items added $10.8M. Capital expenditures of $2.1M left free cash flow of $75.4M.
Questions
What was Krystal Biotech's revenue in the fourth quarter 2025?
Krystal Biotech (KRYS) reported revenue of $107M for the fourth quarter 2025 (Q4 2025), +18% from a year earlier and +10% from the quarter before.
Was Krystal Biotech profitable in the fourth quarter 2025?
Operating profit was $44.3M (41.3% of revenue) and net earnings $51.4M.
Source: Krystal Biotech 10-K on SEC EDGAR.